In Vitro Antibacterial Activity of the Ceftazidime-Avibactam (NXL104) Combination against Pseudomonas aeruginosa Clinical Isolates

被引：94

作者：

Levasseur, Premavathy ^{[1
]}

Girard, Anne-Marie ^{[1
]}

Claudon, Monique ^{[1
]}

Goossens, Herman ^{[2
]}

Black, Michael T. ^{[1
]}

Coleman, Kenneth ^{[1
]}

Miossec, Christine ^{[1
]}

机构：

[1] Novexel SA, Romainville, France

[2] Univ Antwerp Hosp, Vaccine & Infect Dis Inst, Dept Microbiol, Edegem, Belgium

来源：

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY | 2012年 / 56卷 / 03期

关键词：

D O I：

10.1128/AAC.06064-11

中图分类号：

Q93 [微生物学];

学科分类号：

071005 ; 100705 ;

摘要：

The beta-lactamase inhibitor avibactam (NXL104) displays potent inhibition of both class A and C enzymes. The in vitro antibacterial activity of the combination ceftazidime-avibactam was evaluated against a clinical panel of Pseudomonas aeruginosa isolates. Avibactam offered efficient protection from hydrolysis since 94% of isolates were susceptible to ceftazidime when combined with 4 mu g/ml avibactam, compared with 65% susceptible to ceftazidime alone. Ceftazidime-avibactam also demonstrated better antipseudomonal activity than imipenem (82% susceptibility), a common reference treatment.

引用

收藏

页码：1606 / 1608

页数：3

相关论文

共 10 条

[1] In vitro activity of AVE1330A, an innovative broad-spectrum non-β-lactam β-lactamase inhibitor [J].

Bonnefoy, A ;

Dupuis-Hamelin, C ;

Steier, V ;

Delachaume, C ;

Seys, C ;

Stachyra, T ;

Fairley, M ;

Guitton, M ;

Lampilas, M .

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2004, 54 (02) :410-417

[2]

Clinical and Laboratory Standards Institute, 2011, M100S21 CLIN LAB STA, V31, pM100

[3] Antibacterial-Resistant Pseudomonas aeruginosa: Clinical Impact and Complex Regulation of Chromosomally Encoded Resistance Mechanisms [J].

Lister, Philip D. ;

Wolter, Daniel J. ;

Hanson, Nancy D. .

CLINICAL MICROBIOLOGY REVIEWS, 2009, 22 (04) :582-+

[4] In vitro activity of ceftazidime+NXL104 against Pseudomonas aeruginosa and other non-fermenters [J].

Mushtaq, Shazad ;

Warner, Marina ;

Livermore, David M. .

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2010, 65 (11) :2376-2381

[5] Interplay of efflux system, ampC, and oprD expression in carbapenem resistance of Pseudomonas aeruginosa clinical isolates [J].

Quale, J ;

Bratu, S ;

Gupta, J ;

Landman, D .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2006, 50 (05) :1633-1641

[6]

Souli M, 2008, EUROSURVEILLANCE, V13, P1

[7] In vitro activity of the β-lactamase inhibitor NXL104 against KPC-2 carbapenemase and Enterobacteriaceae expressing KPC carbapenemases [J].

Stachyra, Therese ;

Levasseur, Premavathy ;

Pechereau, Marie-Claude ;

Girard, Anne-Marie ;

Claudon, Monique ;

Miossec, Christine ;

Black, Michael T. .

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2009, 64 (02) :326-329

[8] Impact of Multidrug-Resistant Pseudomonas aeruginosa Bacteremia on Patient Outcomes [J].

Tam, Vincent H. ;

Rogers, Cary A. ;

Chang, Kai-Tai ;

Weston, Jaye S. ;

Caeiro, Juan-Pablo ;

Garey, Kevin W. .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2010, 54 (09) :3717-3722

[9] INTERPRETING CHROMOSOMAL DNA RESTRICTION PATTERNS PRODUCED BY PULSED-FIELD GEL-ELECTROPHORESIS - CRITERIA FOR BACTERIAL STRAIN TYPING [J].

TENOVER, FC ;

ARBEIT, RD ;

GOERING, RV ;

MICKELSEN, PA ;

MURRAY, BE ;

PERSING, DH ;

SWAMINATHAN, B .

JOURNAL OF CLINICAL MICROBIOLOGY, 1995, 33 (09) :2233-2239

[10] In Vitro Activity of Ceftazidime Combined with NXL104 versus Pseudomonas aeruginosa Isolates Obtained from Patients in Canadian Hospitals (CANWARD 2009 Study) [J].

Walkty, A. ;

DeCorby, M. ;

Lagace-Wiens, P. R. S. ;

Karlowsky, J. A. ;

Hoban, D. J. ;

Zhanel, G. G. .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2011, 55 (06) :2992-2994